Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 5Peripheral Nervous System Diseases 4Breast Neoplasms 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Head and Neck Neoplasms 3Stomatitis 2Stomach Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Malnutrition 2Colorectal Neoplasms 2Wilms Tumor 1Sarcopenia 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pain 1Oral Complications 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Lymphangioleiomyomatosis 1Lung Neoplasms 1

Interventions

Cyclophosphamide 165fludarabine phosphate 110Peripheral Blood Stem Cell Transplantation 94Mycophenolic Acid 88Whole-Body Irradiation 81Etoposide 81Tacrolimus 73Busulfan 68Melphalan 67Filgrastim 66fludarabine 62Radiotherapy 56Doxorubicin 54Cyclosporine 54Rituximab 50Brentuximab Vedotin 48Antilymphocyte Serum 47Granulocyte Colony-Stimulating Factor 42Vinblastine 41Methotrexate 38Dacarbazine 37Cytarabine 35Gemcitabine 34Nivolumab 30Bleomycin 29Carmustine 28Vincristine 25Prednisone 25Sirolimus 24Bendamustine Hydrochloride 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hodgkin Disease × Glutamine × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡